Development and validation of direct RT-LAMP for SARS-CoV-2

Abu Naser Mohon[1], Jana Hundt[1], Guido van Marle[1], Kanti Pabbaraju[2], Byron Berenger[2,3],

Thomas Griener[3], Luiz Lisboa[3], Deirdre Church[3,4,5], Markus Czub[6], Alexander Greninger[7], Keith

Jerome[8], Cody Doolan[9], Dylan R. Pillai [1,3,4,5]

1. Department of Microbiology, Immunology, and Infectious Diseases, University of
Calgary, AB, Canada

2. Alberta Public Health Laboratory, Calgary, AB, Canada

3. Clinical Section of Microbiology, Alberta Precision Laboratories, Calgary, AB, Canada
4. Department Pathology and Laboratory Medicine, University of Calgary, Calgary, AB,
Canada
5. Department of Medicine, University of Calgary, Calgary, AB, Canada
6. Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada
7. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA

8. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center,
Seattle, WA, USA

9. Illucidx Inc., Calgary, AB, Canada
17

Abstract

We have developed a reverse-transcriptase loop mediated amplification (RT-LAMP) method targeting

genes encoding the Spike (S) protein and RNA-dependent RNA polymerase (RdRP) of SARS-CoV-2. The

LAMP assay achieves comparable limit of detection as commonly used RT-PCR protocols based on

artificial targets, recombinant Sindbis virus, and clinical samples. Clinical validation of single-target (S

gene) LAMP (N=120) showed a positive percent agreement (PPA) of 41/42 (97.62%) and negative

percent agreement (NPA) of 77/78 (98.72%) compared to reference RT-PCR. Dual-target RT-LAMP (S and

RdRP gene) achieved a PPA of 44/48 (91.97%) and NPA 72/72 (100%) when including discrepant

samples. The assay can be performed without a formal extraction procedure, with lyophilized reagents

which do need cold chain, and is amenable to point-of-care application with visual detection.

Corresponding author: Dylan Pillai MD, PhD, 9-3535 Research Road NW, 1W-416
Calgary, AB, Canada, T2L2K8, drpillai@ucalgary.ca, T: 403-770-3338, F: 403-770-3347
30

Introduction

Over the last several decades, we have witnessed the rise of both known and novel viruses, including

human immunodeficiency virus (HIV), SARS coronavirus (SARS-CoV), MERS-CoV, influenza H1N1, Ebola

virus (EBOV), Dengue (DENV), Chikungunya (CHIK), Zika (ZIKV), and most recently 2019 novel

coronavirus (SARS-CoV-2/COVID-19)(1). Most of these emerging viral infections have been triggered by a

direct zoonotic (animal-to-human) transmission event or enhancement, proliferation and spread of

vectors such as the mosquito in new geographic areas. In December 2019 and early January 2020, a

cluster of pneumonia cases from a novel coronavirus, SARS-CoV-2, was reported in Wuhan, China (2–4).

SARS-CoV-2 has now resulted in a global pandemic with the epicentre at the time of writing in Europe

and North America (5). A common theme in the public health response to COVID19 and similar threats is

the lack of rapidly deployable testing in the field to screen large numbers of individuals in exposed areas,

international ports of entry, and testing in quarantine locations such as the home residences, as well as

low-resourced areas (6). This hampers case finding and increases the number of individuals at risk of

exposure and infection. With the ease of travel across continents, delayed testing and lack of screening

programs in the field, global human-to-human transmission will continue at high rates. These factors

make a pandemic very difficult to contain. Early identification of the virus and rapid deployment of a

targeted point of care test (POCT) can stem the spread through immediate quarantine of infected

persons(7). We used existing viral genome sequences to develop a SARS-CoV-2 loop mediated

amplification (LAMP) assay for clinical use and evaluated whether an extraction-free and instrument-

free approach could be achieved(8, 9). POCT requires portability and low complexity without reliance on

sophisticated extraction and read-out instrumentation. Furthermore, LAMP relies on an alternate set of

reagent chemistry that does not depend on or hinder critical elements of the RT-PCR supply chain which

is now under duress (10). Our group has previously demonstrated the utility of LAMP for other

infectious agents like malaria and dengue (11–13).

Materials and Methods

Patient samples and Ethics

Clinical samples used in this study were standard nasopharyngeal (NP) swabs in viral transport medium

(VTM). Specifically, archival samples were sourced from the University of Washington, Seattle, USA and

extracted viral RNA from the Alberta Public Health Laboratory. Ethical approval for use of the archived

samples was obtained from the Conjoint Health Research Ethics Board (CHREB) of the University of

Calgary (REB20-0402). The use of de-identified specimens was deemed non-human subject work by the

University of Washington Institutional Review Board (IRB).

LAMP primer design

Genomic sequences (cDNA) of the SARS-CoV-2 were retrieved from the GenBank database

(https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/) and multiple sequence alignment analysis

(https://www.ebi.ac.uk/Tools/msa/clustalo/) was conducted with other related viruses. From the

multiple sequence alignment, several regions unique to the SARS CoV-2 were identified using our own

algorithms developed in collaboration with Illucidx Inc. (Calgary, AB). LAMP primer sets were designed

targeting unique regions of the Spike (S) protein gene, RNA-dependent RNA Polymerase gene (RdRP),

and parts of the Open Reading Frame (ORF) 1a/b. Five sets of LAMP primers were selected for

laboratory analysis, where Set 1 and Set 2 targeted the non-structural protein (nsp) 3 region in the

ORF1a/b gene and S protein gene, respectively; and Sets 3, 4, and 5 were designed to amplify different

regions of RdRP gene of SARS CoV-2 (Table 1). For the external LAMP amplification control, primers

were used against bacteriophage MS2 as previously described (14).

Design of artificial viral target for LAMP assay verification

Four fragments of specific SARS-Co-V2 regions (ORF1ab (nsp 3,10-11), RdRP (nsp 12), and spike (S)) were

synthesized by SGI-DNA Inc. (San Diego, CA). Fragments were ligated to make one large concatenated

DNA template using the BioXP3200 (SGI-DNA, San Diego, CA) automated Gibson assembly system. The

final template was 1097 base pairs long containing concatenated ORF1a/b (nsp 3)-Spike protein-RdRP

(nsp 12) - ORF1a/b (nsp 10-11) fragments together with flanking plasmid sequence in that order.

Reverse transcription PCR (RT-PCR) assays used in this study

The RT-PCR assays used in this study were performed according to previous publications for the E

gene(15) and N2 gene(16). The E gene RT-PCR was performed with modification according to the Alberta

Public Health Laboratory reference method (17). The modifications included the addition of GC clamps

at the 3' end of the primers and the shortening and addition of a minor groove binding (MGB) moiety to

the hydrolysis probe. Five (5) μL of input template was used to perform the RT-PCR reactions on the

same day when RT-LAMP was performed. A maximal Ct value cut-off of 40 was used to determine

positivity for all RT-PCR reactions.

LAMP assay conditions

The single-target LAMP reaction was conducted using a combination of Warmstart Rtx Reverse

Transcriptase (New England Biolab, Whitby, ON) with *Bst 2.0* Warmstart DNA Polymerase (New England

Biolab, Whitby, ON). In a 25 μL LAMP reaction mixture, 1.6 μM F1P and B1P, 0.8 μM LPF and LPB, 0.2 μM

F3 and B3 primer concentrations, 8mM $MgSO_4$, 1.4 mM dNTPs, 8 unit of *Bst* 2.0 WarmStart® DNA

Polymerase and 7.5 unit of Warm Start® reverse transcriptase were used. The assay was optimized with

pre-addition of 0.5μL of 50X SYBR green (Invitrogen, Burlington, ON) in the 25 μL reaction mixture. For

all LAMP experiments, 10 μL of template was used in the 25 μL reaction mixture. For dual-target LAMP,

identical reagent composition was used except the primers (6 per target) that were added at double

concentration and one half the volume for each primer set. Amplification was measured through

increased relative fluorescence units (RFU) per minute in the CFX-96 Real-Time PCR detection system

(Bio-Rad, Mississauga, ON) or fluorescence values on the QuantStudio 5 RT system (ThermoFisher,

Toronto, ON). RFU values above 100 on the CFX-96 instrument or greater than 100,000 on the

QuantStudio 5 instrument were considered positive when associated with a typical amplification curve

before a 30-minute reaction time. Each primer set was used to amplify the artificial viral DNA target at

different temperature (61°C, 63°C, and 65°C) for a maximum LAMP assay run time of 40 minutes.

Visual detection of the LAMP without instrumentation

A positive LAMP assay was detected visually by the pre-addition of 0.5µL colorimetric fluorescence

indicator (CFI). CFI was made up of the combination of 0.7% (v/v) 10000X Gelgreen (Biotium, Freemont,

CA) in 12 mM Hydroxynapthol blue resuspended in dH_2O (Sigma-Aldrich, Oakville, ON). After the 30-

minute LAMP reaction time, the tubes were exposed to blue LED light using a Blue Light Transilluminator

(New England Biogroup, Atkinson, NH) to visualize the green fluorescence.

Lyophilized LAMP without the need for cold chain

In order to determine if the LAMP primers and master mix could be lyophilized, oligonucleotides were

shipped to Pro-Lab Diagnostics (Toronto, Canada) and lyophilized with GspSSD2 isothermal master

mixture (Optigene, UK). The lyophilized primer, enzyme, master mix combination was hydrated in 15 µL

of resuspension buffer (Pro-Lab Diagnostics) to which 10 µL of the sample was added. Both direct LAMP

(see method described later) and kit-based RNA extractions were performed in this way.

Limit of detection studies

Limit of detection of the LAMP assay was evaluated in three different ways. Initially, copy number of the

synthesized DNA fragment was determined by comparing concentration and molecular weight.

Subsequently, the template solution was serially diluted to achieve a range from 5,000,000 to 5 copies

per reaction. These serially diluted templates were tested by all primers sets. Secondly, the extracted

RNA from one patient specimen was 10-fold serially diluted and tested with the LAMP assay and two RT-

PCR assays used by reference laboratories targeting both the E gene(15) and N2 gene(16). Finally, the

artificial template containing the targeted sequences of interest was cloned into Sindbis Virus (SV) viral

vector system (SINrep5) containing green fluorescent protein (EGFP) and then transfected into BHK-21

cell lines(18)'(19). An approximate estimation of the viral titer was determined by comparing EGFP

expressing foci forming units in BHK-21 as described previously. EGFP forming units ranging from 10^6 –

10^8/mL were obtained for various recombinant virus stocks. Maintenance of the SARS/CoV2-targetted

sequences in the recombinant virus was confirmed using RT-PCR with primers targeting the flanking SV

sequences. Virus particles were serially diluted from 100 to 0.001 SV EGFP forming units per μL, and

RNA was extracted with the QiaAmp Viral RNA extraction kit (Qiagen, Toronto, ON). Extracted RNA was

subjected to TURBO™ DNase (ThermoFisher, Toronto, ON) digestion. Dilutions were subjected to LAMP

reactions as described above.

Validation using clinical samples

In total, 42 RT-PCR-positive clinical (n=32), contrived (n=10), and 78 negative NP swab samples were

tested in the single-target S gene LAMP validation study. In the negative panel, four common human

coronavirus RNA (strain 0C43, NL63, 229E, and HKU1), respiratory syncytial virus (RSV), and Influenza

H1N1 clinical samples were included to evaluate the specificity of the test. Contrived samples were

generated by inoculating the artificial gene DNA construct described earlier into VTM from NP swabs.

Extraction of RNA from clinical samples was performed using the NUCLISENS easyMAG system

(Biomerieux, Durham, NC) or QIAamp Viral RNA Mini Kit (Qiagen, Toronto, ON) depending on specimen

source. All samples in the set were tested simultaneously using the E gene RT-PCR described above and

S gene LAMP (primer set 2). Discrepant analysis was performed by performing the CDC N2 gene(16) RT-

PCR assay. For the LAMP assay, 10 μL of the RNA extract was used for each reaction. A second validation

study was performed for the dual-target LAMP (S gene and RdRP). Here, RT-PCR-positive clinical (n=34),

contrived (n=10), and 72 negative NP swab samples were tested. All LAMP reactions for the clinical

validation studies was performed using the combination of Warmstart Rtx Reverse Transcriptase with

Bst 2.0 Warmstart DNA Polymerase as described earlier.

Direct LAMP assay without formal extraction

A direct LAMP assay was also conducted to establish an extraction-free approach. In this scheme, the

LAMP reaction mixture was prepared without the enzymes. 9.5 μL reaction mixture containing all

reagents except the enzymes was added to 14 μL of the 10-fold serially diluted NP VTM sample. For

direct LAMP, VTM must be diluted 1:10 (v/v) with dH_20 prior to addition. The mixture was then heated

at 95°C for 3, 5, and 10 minutes to both inactivate virus and presumptively release viral RNA. Finally, *Bst*

2.0 WarmStart® DNA Polymerase (1 μL) and Warm Start® reverse transcriptase (0.5 μL) were directly

added to the reaction mixture and the LAMP assay was carried out as above. Due to evaporative loss,

boil steps should have excess volume to ensure adequate input template for LAMP reactions.

In silico analysis of primer combinations to determine cross-reactivity

A blast search alignment (https://blast.ncbi.nlm.nih.gov/Blast.cgi) for primers in set 2 (spike gene) and

set 3 (RdRP gene) were performed against a critical list of infectious agents that cause upper respiratory

tract infections. A nucleotide local alignment using BLASTn with the default parameters was performed

against the National Center of Biotechnology Information (NCBI) Nucleotide database.

Results

Verification of SARS-CoV-2 LAMP primer sets on artificial gene targets

In order to determine the limits of detection of the five LAMP primer sets designed for SARS-CoV-2,

experiments were conducted using an artificial gene target construct. Three targets (Figure 1) selected

were the Spike (S) protein gene, the RNA-dependent RNA polymerase (RdRP) region (nsp 12), and nsp 3

region in the open reading frame (ORF) 1a/b protein encoding gene sequence. Figure 2 shows the

amplification curves for the five primer sets used in this study. Based on time to positivity, primer sets 1,

2, and 3 demonstrated the fastest positive reaction time, suggesting optimal performance in the LAMP

assay at 50 copies of the artificial target per reaction. When tested at 5 copies per reaction, primer set 2

targeting the S gene showed the best limit of detection. An *in silico* analysis of primer set 2 (S gene) and

set 3 (RdRP) demonstrated no significant sequence alignment cross-reactivity with known upper

respiratory tract infectious pathogens (data not shown).

Visual detection of SARS-CoV-2 LAMP amplification

An advantage of LAMP is the ability to detect amplification with the naked eye either via the use of

colorimetric or fluorescent dyes. To test this, LAMP was conducted using the S gene LAMP primer set

using the artificial gene target. Figure 3 shows a positive test based on fluorescent detection using a blue

light emitting diode (LED). A serial dilution between 50×10^7 and 5 copies per reaction of the artificial

gene construct is shown with a limit of detection of 50 copies per reaction obtained. The LAMP assay

using enzyme GspSSD2 was also performed using a lyophilized master mix. Studies were performed with

both kit-based RNA extracted clinical samples as well as using the direct LAMP method described later.

These data showed that amplification occurred up to a 1000-fold dilution of a clinical sample with the

direct LAMP method (data not shown).

Limit of detection studies using recombinant Sindbis virus (SV) containing SARS-CoV-2 targets

In order to determine LOD based on viral titer, recombinant RNA viral vector from Sindbis virus (SV)

containing SARS-CoV-2 targets was generated. LAMP was performed using Set 2 (S gene) alone and in

combination with Set 3 (RdRP region (nsp 12)). The primer sets in question achieved a LOD of 0.1-1.0 SV

EGFP forming units per μL for the S gene alone and the dual-target LAMP amplifying both S and RdRP

genes in a single reaction (Table 2). One SV EGFP focus forming unit (FFU) roughly corresponds to 1.0

infectious viral particle given the assumption that one virus particle infects one cell.

Direct LAMP detection of SARS-CoV-2 without formal extraction

Given extraction reagent supply chain shortages, we tested the ability of LAMP using the S gene to

amplify a SARS-CoV-2 positive nasopharyngeal swab specimen without a formal extraction procedure.

The VTM was heated at 95°C for 3, 5 and 10 minutes and then subjected to the S gene LAMP procedure

in a serial dilution experiment. This experiment was performed in a head-to-head comparison with the

same specimen tested after formal extraction. Figure 4 demonstrates that amplification occurred with

direct LAMP up to a dilution of 100,000-fold with a 95°C for 3 minutes heat step in a single experiment.

Table 3 shows the data for direct LAMP compared to LAMP and RT-PCR from RNA extracts in triplicate

experiments. Reproducible amplification with direct LAMP (95°C for 3 minutes) occurred at a dilution

factor of 1,000-fold, whereas LAMP from an RNA extract was successful reproducibly at a dilution of

100,000-fold.

Limit of detection studies using SARS-CoV-2 LAMP on nasopharyngeal swab clinical samples

Serial dilution experiments were conducted using a single positive SARS-CoV-2 nasopharyngeal swab

specimen. The viral transport media (VTM) was diluted serially between 10 to 1,000,000-fold. The

dilutions were tested in triplicate to determine the results of LAMP and two reference RT-PCR methods

(Envelope [E] gene and Nucleocapsid [N] 2 gene). Both RT-PCR and the RT-LAMP (S gene) amplified the

target up to a dilution of 100,000 in a head-to-head comparison, suggesting equal LOD (data not shown).

The same experiment was conducted comparing E gene RT-PCR to RT-LAMP (dual-target S and RdRP

gene) as well as a direct RT-LAMP (dual-target S and RdRP gene) without formal extraction (boil method)

on a separate specimen. These data are shown in Figure 5 and Table 4. Reproducible amplification

occurred at 1000-fold dilution for RT-PCR (E gene) and RT-LAMP. Direct-LAMP amplified reproducibly at

a 100-fold dilution for this sample.

Clinical validation of SARS-CoV-2 LAMP using nasopharyngeal swab samples

A sample set of nasopharyngeal swabs (n=108) from COVID-positive, COVID-negative, together with

samples for other respiratory viruses were used to validate the S gene LAMP primer set (Table 5). Given

no gold standard exists, percent positive agreement (PPA) and negative percent agreement (NPA) were

calculated. Reference methods included RT-PCR (E gene and N2 gene) methods employed by reference

laboratories. Using the RT-PCR (E gene) as a reference standard, there was 41/42 (97.62% (95% CI 87.43

- 99.94)) PPA and 77/78 (98.72% (95% CI 93.06 - 99.97)) NPA for the S gene LAMP. No cross-reactivity

was observed for human coronaviruses (HCoV) OC43, 229E, NL63, and HKU1 or influenza virus A (H1N1)

pdm09. Resolution of discrepant results (Table 6) revealed that one falsely positive LAMP result was

positive based on the original RT-PCR result reported at the time of clinical testing and therefore

represented a true positive that may be due to sample decay in storage. The second falsely negative

sample was positive by all methods including the RdRP LAMP primer set and was deemed a false

negative in the final analysis. In order to eliminate the concern for S gene false negatives, dual-target S

and RdRP LAMP was performed to increase clinical sensitivity. This second clinical sample set

intentionally included low positive (high Ct value) specimens. Table 7 demonstrates PPA of 44/48

(91.67% (95% CI 80.02 - 97.68)) and NPA 72/72 (100.00% (95% CI 95.01 - 100.00)) for the dual LAMP

compared to the RT-PCR E gene reference method. Discrepant analysis (Table 8) revealed that all four

falsely negative samples by LAMP were in fact positive by the CDC N2 RT-PCR, confirming the false

negative status. The four discrepant specimens were repeated with single-target S gene LAMP and were

also negative.

Discussion

The global pandemic with SARS-CoV-2 has resulted in the need for diagnostic test development at a

scale never seen before. Rapid deployment of validated laboratory-developed diagnostic tests or

commercial tests was essential to the containment of the virus as it allows for self-quarantine measures

to be imposed in a strategic fashion before widespread community transmission occurs (6, 7) .

Diagnostic tests have to be analytically sensitive in order to not to miss any cases in the acute phase of

viremia (11). As such, NAATs serve this purpose. In particular, RT-PCR has been employed as the primary

diagnostic counter-measure (20). However, reagent supply chains for key items are under immense

pressure. Local solutions to reagent sources have become paramount because barriers to trade of these

selected items have been a concern.

We noted that a one false negative occurred with single-target LAMP (S gene) for a lower Ct value

sample that may be due to genetic polymorphism at key residues where LAMP primers bind. This issue

was overcome by using two targets (S and RdRP genes) simultaneously. The single and dua-target RT-

LAMP test for SARS-CoV-2 has comparable analytical sensitivity and achieved excellent agreement with

the reference method. We noted that at high Ct value (>35), and presumably low-level infection, E gene

RT-PCR identified specimens that LAMP did not. This suggests the LOD of the RT-PCR used in this study

may be superior to LAMP for these low positives. However, we note that samples with E gene RT-PCR Ct

values greater than 35 are relatively rare (~1%) at our reference laboratory (our unpublished

observations). Increasing LAMP reaction times may reduce false negatives, but also lead to spurious

amplification. The clinical relevance of these low positives is still not well understood and could

represent early infection during the incubation period, late infection after the initial viral peak, or

asymptomatic carriage. The transmissibility of these low positives to others is also not well understood.

Moreover, if we assume an overall prevalence of 5%, the negative predictive value of LAMP is 99.56%

(95% CI 98.89 - 99.83) and positive predictive value is 100%. These values clearly support the use of

LAMP as an alternative NAAT.

LAMP does not rely on the same reagents as RT-PCR and thus alleviates pressure on key supply chain

items. The LAMP method is amenable to high throughput testing in either 96-well or 384-well. The assay

is also able to detect SARS-CoV-2 in VTM without the need for a kit-based RNA extraction method

relying on commercial reagents. However, we noted a 2-log drop in analytical sensitivity when direct

LAMP was performed following this heat step. The drop in analytical sensitivity will only affect low-level

viral load specimens. This is still within a good range compared to RT-PCR using RNA isolation. We

believe that addition of a buffer to stabilize the RNA-enzyme complex in the LAMP reaction may further

enhance this extraction-free approach. This needs to be tested. The heat step at 95°C for 3 minutes

should significantly inactivate the virus permitting safe operation of the assay in a Class II biosafety

cabinet (21). Taken together, these data support the use of LAMP chemistry as an alternate method for

laboratory developed NAATs.

Our studies with a LAMP enzyme called GspSSD2 also provided encouraging results. These data

demonstrated that lyophilized GspSSD2 and reagents are able to amplify SARS-CoV-2 directly from a

specimen without a kit-based RNA extraction. Additionally, visual detection with a simple blue LED light

is able to discriminate positive from negative. These features are particularly useful for resource-limited

settings without sophisticated laboratory infrastructure or where the cost of or access to kit-based

reagents and equipment are prohibitive. Further studies are required to clinically validate this low-cost

approach.

Limitations of the study include not testing other sample types such as alternate swabs, nasal washes,

oropharyngeal samples, sputum, or stool. This work is ongoing with a special emphasis on swab-free

testing. Also formal SARS-CoV-2 viral titers were not calculated in the limit of detection studies.

Nevertheless, LAMP presents a much needed alternative approach to SARS-CoV-2 diagnostic testing that

is available for deployment immediately in a LDT format as it relies on other key reagents that do not

cannibalize RT-PCR reagents. Ultimately, the aim is to port LAMP chemistry on a stand-alone microfluidic

device POCT to be deployed in the community, either at ports of entry, homes, pharmacies, or resource-

limited settings.

Acknowledgments

Dr. Ranmalee Amarasekara for expert technical assistance, Daniel Castaneda Mogollon for performing

bioinformatics analysis, and Omar Abdullah for research analytical support.

Funding Statement

Funding for this study was obtained from the Canadian Institutes for Health Research (NFRFR-2019-

00015, DRP) and Genome Canada (DRP), and from the M.J. Murdock Charitable Trust (KRJ).

Conflicts of Interest

ANM and DRP have a patent on LAMP technology. CD is an employee of Illucidx Inc.

References

1.   Reperant LA, Osterhaus ADME. 2017. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? Vaccine 35:4470–4474.

2.   Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382:1199–1207.

3.   Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273.

4.   Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-Z. 2020. A new coronavirus associated with human respiratory disease in China. Nature 579:265–269.

5.   CDC COVID-19 Response Team. 2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 69:343–346.

6.   Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S, Yansouni CP. 2020. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review. Ann Intern Med.

7.   Nguyen T, Duong Bang D, Wolff A. 2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics. Micromachines 11.

8.   Forster P, Forster L, Renfrew C, Forster M. 2020. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A.

9.   Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond Engl 395:565–574.

10.   Ivanov D. 2020. Predicting the impacts of epidemic outbreaks on global supply chains: A simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case. Transp Res Part E Logist Transp Rev 136:101922.

11.   Sigera PC, Amarasekara R, Rodrigo C, Rajapakse S, Weeratunga P, De Silva NL, Huang CH, Sahoo MK, Pinsky BA, Pillai DR, Tissera HA, Jayasinghe S, Handunnetti S, Fernando SD. 2019. Risk prediction for

severe disease and better diagnostic accuracy in early dengue infection; the Colombo dengue study. BMC Infect Dis 19:680.

12.   Mohon AN, Getie S, Jahan N, Alam MS, Pillai DR. 2019. Ultrasensitive loop mediated isothermal amplification (US-LAMP) to detect malaria for elimination. Malar J 18:350.

13.   Girma S, Cheaveau J, Mohon AN, Marasinghe D, Legese R, Balasingam N, Abera A, Feleke SM, Golassa L, Pillai DR. 2018. Prevalence and epidemiological characteristics of asymptomatic malaria based on ultrasensitive diagnostics: A cross-sectional study. Clin Infect Dis Off Publ Infect Dis Soc Am.

14.   Benzine JW, Brown KM, Agans KN, Godiska R, Mire CE, Gowda K, Converse B, Geisbert TW, Mead DA, Chander Y. 2016. Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood. J Infect Dis 214:S234–S242.

15.   Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 25.

16.   2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html. Centers for Disease Control and Prevention.

17.   https://www.albertahealthservices.ca/assets/wf/lab/wf-lab-bulletin-COVID-19-test-performance.pdf.

18.   van Marle G, Ethier J, Silva C, Mac Vicar BA, Power C. 2003. Human immunodeficiency virus type 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector. Virology 309:61–74.

19.   Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. 1993. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 67:6439–6446.

20.   Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H, Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit. J Clin Microbiol.

21.   Darnell MER, Subbarao K, Feinstone SM, Taylor DR. 2004. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods 121:85–91.

Figures

Figure 1: Map of the gene fragments from SARS-Co-V2 (Genbank ID MT2078.1) that were used for
synthesizing the genetic construct template. Fragments of ORF1a/b [nsp 3] (3064-3285), ORF1a/b [nsp
10-11] (13328-13622), ORF1a/b RdRP [nsp 12] (15258-15445), and Spike gene (22153-22368) were
concatenated into a single artificial construct. A second template including the E gene was also made for
the purposes of testing the E gene RT-PCR.

Figure 2: Limit of detection of RT-LAMP primer sets designed to detect the SARS-CoV-2 artificial DNA
construct. These data are representative of an experiment performed in triplicate at (A) 500 and (B) 50
copies. Amplification curves for all 5 primer sets are shown: Set 1 (ORF1ab); Set 2 (S gene); and Set 3, 4,
and 5 (RdRP). Based on these experiments, a cut off 30 minutes reaction time was determined for
specific amplification. Fluorescence (QuantStudio 5) on the y-axis is plotted in relation to reaction time
(minutes).

416 Figure 3: Photograph of S gene RT-LAMP (Set 2) performed on the artificial DNA construct. Fluorescence
417 can be detected by naked eye after excitation of gel green in the reaction with a blue LED light. A serial
418 10-fold dilution is shown from 5 x 10^7 copies to 5 copies of the gene construct in this representative
419 experiment (left to right). The last two tubes on the right are negative template controls. A reaction time
420 was set at 30 minutes.
421

435 Figure 4: Single-target (S gene) RT-LAMP amplification of SARS-CoV-2 spike gene from NP swab sample
436 (E gene Ct 21.29) using a simple heat step. A representative direct LAMP experiment is compared to a
437 kit-based extracted RNA (A) for serial dilutions of the neat sample. Heat inactivation without formal
438 extraction is shown in (B) 95°C for 3 minutes (C) 95°C for 5 minutes and (D) 95°C for 10 minutes. Relative
439 fluorescence units (CFX-96) on the y-axis is plotted in relation to reaction time (minutes).
440

442
443

455 Figure 5: Serial dilution studies of a clinical sample (NP swab in VTM, E gene Ct 25.6) comparing the limit
456 of detection of Envelope (E) gene RT-PCR (n=6), S gene + RdRP gene RT-LAMP (n=9) and S gene + RdRP
457 gene direct RT-LAMP (n=9). Cycle threshold (Ct) value (RT-PCR) or time in minutes (LAMP) shown on y-
458 axis. No virus was detected at a dilution of 1 x 10^5 from the original neat sample. Standard deviation of
459 the mean indicated in error bars if more than two values existed.
460

462
463
464

480 **Tables:**

481 Table 1: Primer sets used in this study to perform RT-LAMP. All 5 primer sets are shown: Set 1 (ORF1a/b,

482 nsp3); Set 2 (S gene); and Set 3, 4, and 5 (RdRP).

Primer name	Sequence
S1-F3	AGTTTGAGCCATCAACTCA
S1-B3:	TGAACCTCAACAATTGTTTGA
S1-F1P	CAGGTTGAAGAGCAGCAGAAGTGTACTGAAGATGATTACCAAGG
S1-B1P	AGCAAGAAGAAGATTGGTTAGATGATGTCTGATTGTCCTCACTG
S1-LPF	GGCACCAAATTCCAAAGGT
S1-LPB	AACTGTTGGTCAACAAGACGG
S2-F3	ATTCTAAGCACACGCCTAT
S2-B3	GAAGATAACCCACATAATAAGCT
S2-F1P	ACCTATTGGCAAATCTACCAATGGTTTAGTGCGTGATCTCCCT
S2-B1P	ATCACTAGGTTTCAAACTTTACTTGCCTGTCCAACCTGAAGAAGA
S2-LPF	TTCTAAAGCCGAAAAACCCTG
S2-LPB	CATAGAAGTTATTTGACTCCTGGTG
S3-F3	CACCTTATGGGTTGGGATT
S3-B3	AACATATAGTGAACCGCCA
S3-F1P	GTTTGCGAGCAAGAACAAGTGAATGTGATAGAGCCATGCC
S3-B1P	ATACAACGTGTTGTAGCTTGTCACACATGACCATTTCACTCAA
S3-LPF	GGCCATAATTCTAAGCATGTTA
S3-LPB	ATTAGCTAATGAGTGTGCTCAAGTA
S4-F3	ACATGCTTAGAATTATGGCC
S4-B3	GCTTGACAAATGTTAAAAACACT
S4-F1P	TTGAGCACACTCATTAGCTAATCTATCACTTGTTCTTGCTCGCA
S4-B1P	GAGTGAAATGGTCATGTGTGGCGCATAAGCAGTTGTGGCA
S4-LPF	GACAAGCTACAACACGTTGTATGT

S4-LPB	ACTATATGTTAAACCAGGTGGAACC
S5-F3	ATGGCCTCACTTGTTCTT
S5-B3	TAACATTGGCCGTGACAG
S5-F1P	TTGAGCACACTCATTAGCTAATCTATGCTCGCAAACATACAACG
S5-B1P	GTCATGTGTGGCGGTTCACTACACTATTAGCATAAGCAGTTG
S5-LPF	ACGGTGTGACAAGCTACAACA
S5-LPB	CCAGGTGGAACCTCATCAGGAG

488 Table 2: RT-LAMP assay results on serially diluted recombinant SV virus containing the artificial construct
489 now expressed as RNA. Positive tested replicates/total number of replicates is shown in relation to the
490 approximate viral titer for both single-target (S gene) and dual-target (S and RdRP gene) LAMP reactions.

Approximate viral titer/μL	S gene Single-target RT-LAMP	S gene and RdRP gene Dual-Target RT-LAMP
100	3/3	3/3
10	3/3	3/3
1	3/3	3/3
0.1	2/3	2/3
0.01	0/3	1/3
0.001	0/3	0/3

492 Table 3: Single-target (S gene) RT-LAMP assay results on a NP swab VTM sample (E gene Ct 21.29) containing SARS-Co-V2 compared to RT-LAMP
493 and RT-PCR after kit-based RNA extraction. Positive tested replicates/total number of replicates for a single representative triplicate experiment
494 is shown. Dilutions are based on 10-fold serial dilutions from a neat NP VTM sample. Kit-based extraction is compared to direct RT-LAMP
495 procedures including a heat step.

Sample dilution factor	E gene RNA extract RT-PCR	N2 gene RNA extract RT-PCR	RT-LAMP RNA extract	Direct RT-LAMP 10 min/95°C	Direct RT-LAMP 5 min/95°C	Direct RT-LAMP 3 min/ 95°C
10	3/3	3/3	3/3	3/3	3/3	3/3
100	3/3	3/3	3/3	3/3	3/3	3/3
1000	3/3	3/3	2/3	1/3	2/3	2/3
10000	3/3	3/3	3/3	0/3	0/3	1/3
100000	2/3	2/3	2/3	0/3	0/3	1/3

506   Table 4: Dual-target RT-LAMP (S and RdRP gene) assay results on a NP VTM sample (E gene Ct 25.6) containing SARS-Co-V2 compared to RT-PCR
507   after kit-based RNA extraction and directly from a sample. Positive tested replicates/total number of replicates from repeated triplicate
508   experiments is shown. Dilutions are based on 10-fold serial dilutions from a neat NP VTM sample.

Sample dilution factor	E gene RNA extract RT-PCR	Dual RT-LAMP RNA extract	Direct dual RT-LAMP 3 min/ 95°C
10	6/6	9/9	9/9
100	6/6	9/9	9/9
1000	6/6	5/9	1/9
10000	1/6	1/9	0/9
100000	0/6	0/9	0/9

510 Table 5: Validation of RT-LAMP (S gene) compared to RT-PCR (E gene) for clinical samples (NP swabs),
511 contrived samples, and negative control samples. PPA - positive percent agreement; NPA - negative
512 percent agreement

RT-LAMP (S gene)	RT-PCR (E gene)		Total
	Positive	Negative	
Positive	41	1	42
Negative	1	77	78
Total	42	78	120
PPA	97.67% (95% CI 87.43 - 99.94)		
NPA	98.72% (95% CI 93.06 - 99.97)		

516 Table 6: Discrepant analysis for single-target (S gene) RT-LAMP from the clinical validation data
517 set.

Sample number	Original RT-PCR (E gene)	Repeat RT-PCR (E gene)	RT-LAMP (S gene)	RT-LAMP (RdRP)	CDC RT-PCR (N2 gene)	CDC RT-PCR Ct value	Final
Sample 4	Positive	Negative	Positive	Negative	Negative	N/A	Positive
Sample 7	Positive	Positive	Negative	Positive	Positive	26.8	Positive

521 Table 7: Validation of dual-target RT-LAMP (S gene and RdRP genes) using a validation set of
522 clinical samples. PPA - positive percent agreement; NPA - negative percent agreement

RT-LAMP (S + RdRP)	RT-PCR (E gene)		Total
	Positive	Negative	
Positive	44	0	44
Negative	4	72	76
Total	48	72	120
PPA	91.67% (95% CI 80.02 - 97.68)		
NPA	100.00% (95% CI 95.01 - 100.00)		

523 Table 8: Discrepant analysis for dual-target (S + RdRP gene) RT-LAMP for samples with high Ct
524 values from the clinical validation data

Sample number	Original RT-PCR (E gene)	Repeat RT-PCR (E gene)	RT-LAMP (S + RdRP gene)	RT-LAMP (S gene)	CDC RT-PCR (N2 gene)	CDC RT-PCR Ct value	Final
Sample A7	Positive	Positive	Negative	Negative	Positive	38.36	Positive
Sample A8	Positive	Positive	Negative	Negative	Positive	36.19	Positive
Sample B7	Positive	Positive	Negative	Negative	Positive	36.41	Positive
Sample D5	Positive	Positive	Negative	Negative	Positive	35.39	Positive